Beyond the numbers, Vytrus has managed to draw a bridge between the avant -garde science, real sustainability and business profitability. Its evolution is a paradigmatic case of how biotechnology can be the engine of a resilient, innovative and aligned growth model with the new investment vectors: health, longevity and esg.
Profitable and sustainable biotechnology
Vytrus closed 2024 overcoming the 5 million euros in billing, a +35% compared to the previous yearwith a Ebitda of 2 million (+55%) and a 1 million net profit (+87%). This financial scalability has been possible thanks to a business model based on 100% natural active ingredientspatentable and obtained by plant biotechnology from stem cells, with savings of 99% in water consumption with respect to traditional plant extractsâ € ‹. The company saved 64 thousand tons of water in its production processes in 2024 thanks to the purchases of its customers, almost 31% compared to 2023 (49 thousand tons).
This approach not only improves operational margins but also responds to growing interest of the final consumer in effective productsbut also safe and responsible with the environment. Vytrus has been recognized in 2024 with the Ecovadis Platinum label, a distinctive for good sustainability practices to which only 1% of the companies evaluated globally access (+150,000 companies). In addition, their sales in 39 countries rely on a portfolio of 21 active ingredients, in constant expansion.
Clarivine ™: longevity as a new cosmetic paradigm
In April 2025, Vytrus launched Clarivine ™a new revolutionary ingredient that has received andl Silver Award for Innovation in In-Cosmetics Global 2025among the best cosmetic assets in the world. Developed from vid stem cells, Clavine ™ fuses plant biotechnology and the latest trends in cutaneous longevity and «Skin» Glass «â €‹, imitating the beneficial effects of intermittent fasting on skin health.
This active active cell regenerative routes such as autophagy, protects telomeres and reduces oxidative stress, promoting healthy and visible aging from the inside. With clinically demonstrated efficacy in just 14 days, it offers both immediate and long -term benefits, embodying a new generation of ingredients that not only embellish, but also improve the functional health of the skinâ € ‹.
Science, strategy and expansion
The success of Clarivine ™ is not isolated, but part of a robust strategy. In 2024, Vytrus completed a capital increase of 1.2 million euros led by Boyser (Family Office of Fluidra) to finance its expansion as a multitecnological group. In addition, it has initiated direct marketing in Spain and France, strategic markets in dermocosmetic, and has invested in the expansion of its productive capacity to accompany the planned growth until 2027â € ‹.
Are Strategic Plan 2024-2027 It contemplates reaching 12 million euros in sales, maintaining a solid profitability and raising investment in R & D+I – which already represents 21% of its business figure – as one of the pillars of technological differentiation.
Invest in longevity: a multisectoral horizon
Longevity has ceased to be an exclusive theme of the Preventive Medicine or Nutrition To land strongly in the cosmetic. Ingredients such as Clarivine ™ open new investment possibilities in personal care based on science and sustainability. Vytrus offers a proposal that responds to three major trends that mark the future of investment portfolios: proactive health, integral sustainability and disruptive technology.
In a context where the investor seeks companies with positive impact, scalability and differentiation, Vytrus Biotech demonstrates that it is possible to generate economic and social value through cosmetic biotechnology. The beauty of tomorrow will be scientific, profitable and sustainable. And Vytrus is undoubtedly in the epicenter of that transformation.